Get the Stockscreener App
2.995
4.01%
0.125
Taysha Gene Therapies Inc stock is traded at $2.995, with a volume of 2.49M.
It is up +4.01% in the last 24 hours and up +13.50% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$2.87
Open:
$2.9
24h Volume:
2.49M
Relative Volume:
0.72
Market Cap:
$817.02M
Revenue:
$12.87M
Net Income/Loss:
$-114.34M
P/E Ratio:
-3.464
EPS:
-0.8646
Net Cash Flow:
$-79.23M
1W Performance:
+1.53%
1M Performance:
+13.50%
6M Performance:
+85.40%
1Y Performance:
+33.26%
1-Day Range:
$2.854
$3.01
1-Week Range:
$2.7638
$3.05
52-Week Range:
$1.05
$3.31
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.995 | 799.29M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.88 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.54 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.91 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.43 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.19 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Taysha Gene Therapies Inc. Stages Intraday Comeback — Trend ChangeJuly 2025 Big Picture & Long-Term Growth Portfolio Plans - thegnnews.com
BofA Securities Affirms ‘Buy’ Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects - MSN
Wells Fargo Raises Taysha Gene Therapies Target Price to $8.00 Amid 'Overweight' Rating - AInvest
Institutional Investors Are Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Biggest Bettors and Were Rewarded After Last Week's US$199m Market Cap Gain - 富途牛牛
Taysha Gene Therapies Inc. Consolidation Zone May Signal Accumulation2025 Fundamental Recap & Real-Time Volume Analysis Alerts - metal.it
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome treatment boosts stock outlook - Investing.com Nigeria
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome treatment boosts stock outlook By Investing.com - Investing.com South Africa
Taysha Gene Therapies price target raised to $14 from $11 at Canaccord - MSN
Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - The Globe and Mail
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $8 to $14 - 富途牛牛
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Outlook for Taysha Gene Therapies: Buy Rating Reinforced by Strong Financial Position and Promising Clinical Progress - TipRanks
Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress By Investing.com - Investing.com South Africa
Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress - Investing.com Canada
Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028 - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates - MSN
Taysha Gene 2025 Q2 Earnings Significant Revenue Growth Despite Worsening Net Loss - AInvest
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... By GuruFocus - Investing.com Canada
Taysha Gene Therapies Advances Rett Syndrome Trials - TipRanks
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - 富途牛牛
Chardan Capital Keeps Buy Rating on Taysha Gene with PT Raised to $10 - AInvest
Taysha Gene Therapies shares rise 6.70% intraday after reporting Q2 2025 earnings. - AInvest
Transcript : Taysha Gene Therapies, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Taysha Gene Therapies' Q2 2025: Key Contradictions in Clinical Trial Endpoints and Regulatory Strategy - AInvest
Taysha Gene Therapies, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Taysha Gene’s Q2 2025 revenue beats forecast By Investing.com - Investing.com UK
Earnings call transcript: Taysha Gene’s Q2 2025 revenue beats forecast - Investing.com
Taysha Gene Therapies reports Q2 EPS (9c), consensus (8c) - TipRanks
TSHATaysha Gene Therapies, Inc. Latest Stock News & Market Updates - Stock Titan
Is Taysha Gene Therapies Inc. benefiting from interest rate changesSteady Performer Watchlist - mustnews.co.kr
How does Taysha Gene Therapies Inc. perform in inflationary periodsBest Picks for Wealth Multiplication - newsyoung.net
Taysha Gene Therapies Inc. Reaches Critical Trendline SupportAlpha Focused Technical Trade Signals Gain Attention - beatles.ru
Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds - insights.citeline.com
Taysha Gene TSHA Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships and Innovation - AInvest
Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA) - MSN
Taysha Gene Therapies Inc. Breaks Losing Streak — Is the Trend ReversingPortfolio Diversification Stock Ideas From Experts - beatles.ru
Taysha Gene Therapies Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Earnings Preview: TSHA to Report Financial Results Pre-market on August 12 - 富途牛牛
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 - 富途牛牛
Taysha Gene Therapies to Release Second Quarter 2025 - GlobeNewswire
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance
RSI Crosses Above 30 for Taysha Gene Therapies Inc. — Reversal in SightCommunity Shared Smart Money Signals Show Movement - beatles.ru
What are analysts’ price targets for Taysha Gene Therapies Inc. in the next 12 monthsDiscover undervalued stocks before they soar - Jammu Links News
What are Taysha Gene Therapies Inc. company’s key revenue driversBuild wealth with steady, reliable stocks - Jammu Links News
How many analysts rate Taysha Gene Therapies Inc. as a “Buy”Maximize gains with data-driven stock picks - Jammu Links News
What analysts say about Taysha Gene Therapies Inc. stockSuperior trading gains - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
What is Taysha Gene Therapies Inc. company’s growth strategyTriple returns potential - Jammu Links News
Is Taysha Gene Therapies Inc. stock overvalued or undervaluedUnlock real-time stock alerts for quick profits - Jammu Links News
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):